INDICATIONS FOR USE:

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>ICD10</th>
<th>Regimen Code</th>
<th>*Reimbursement Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pertuzumab is indicated in combination with trastuzumab and PACLitaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to or are deemed clinically unsuitable for DOCEtaxel</td>
<td>C50</td>
<td>00507a</td>
<td>Pertuzumab-ODMS Feb 2014 Trastuzumab-Hospital PACLitaxel-Hospital</td>
</tr>
</tbody>
</table>

If the reimbursement status is not defined, the indication has yet to be assessed through the formal HSE reimbursement process.

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Treatment is administered every 21 days in responding patients until disease progression or unacceptable toxicity develops.

Facilities to treat anaphylaxis MUST be present when trastuzumab and pertuzumab are administered.

Table 1: Cycle 1: Pertuzumab and trastuzumab loading doses

<table>
<thead>
<tr>
<th>Order of Admin</th>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Diluent &amp; Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 or 2</td>
<td>1</td>
<td>Pertuzumab</td>
<td>840mg</td>
<td>IV Observe for 1hr post infusion</td>
<td>250ml 0.9% NaCl over 60min</td>
</tr>
<tr>
<td>2 or 1</td>
<td>1</td>
<td>Trastuzumab</td>
<td>8mg/kg</td>
<td>IV infusion Observe post infusion</td>
<td>250ml 0.9% NaCl over 90min</td>
</tr>
<tr>
<td>3</td>
<td>1, 8, 15</td>
<td>PACLitaxel</td>
<td>80mg/m²</td>
<td>IV infusion</td>
<td>²250ml 0.9% NaCl over 1hr</td>
</tr>
</tbody>
</table>

*Recommended Observation period: Patients should be observed for at least six hours after the start of the first infusion and for two hours after the start of the subsequent infusions for symptoms like fever and chills or other infusion-related symptoms. Any deviation should be noted in local policies.

²PACLitaxel must be supplied in non-PVC containers and administered using non-PVC giving sets and through an in-line 0.22 μm filter with a microporous membrane. PACLitaxel should be diluted to a concentration of 0.3-1.2mg/ml.
Table 2: Cycles 2 and subsequent cycles

<table>
<thead>
<tr>
<th>Order of Admin</th>
<th>Day</th>
<th>Drug</th>
<th>Dose</th>
<th>Route</th>
<th>Diluent &amp; Rate</th>
<th>Cycle</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 or 2</td>
<td>1</td>
<td>Pertuzumab</td>
<td>420mg</td>
<td>IV infusion</td>
<td>250ml 0.9% NaCl over 60min.</td>
<td>Every 21 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Observe for 30-60mins post infusion(^a)</td>
<td>Reduce to 30min on subsequent doses if no adverse reactions.</td>
<td></td>
</tr>
<tr>
<td>2 or 1</td>
<td>1</td>
<td>Trastuzumab</td>
<td>6mg/kg</td>
<td>IV infusion</td>
<td>250ml 0.9% NaCl over 60min</td>
<td>Every 21 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Observe post infusion(^b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>1, 8 and 15</td>
<td>PACLitaxel</td>
<td>80mg/m(^2)</td>
<td>IV infusion</td>
<td>^250ml 0.9% NaCl over 1hr</td>
<td>Day 1, 8, 15 of a 21 day cycle up to maximum of 8 cycles</td>
</tr>
</tbody>
</table>

\(^a\)Observation period not required after 3 consecutive treatments with pertuzumab with no reaction.

\(^b\)Recommended Observation period: Patients should be observed for at least six hours after the start of the first infusion and for two hours after the start of the subsequent infusions for symptoms like fever and chills or other infusion-related symptoms. Any deviation should be noted in local policies.

\(^2\)PACLitaxel must be supplied in non-PVC containers and administered using non-PVC giving sets and through an in-line 0.22 μm filter with a microporous membrane.

PACLitaxel should be diluted to a concentration of 0.3-1.2mg/ml.

Trastuzumab is incompatible with glucose solution

ELIGIBILITY:
- Indications as above
- HER2 positive as demonstrated by a validated test method
- Life expectancy > 3months
- ECOG status 0-1
- LVEF ≥ 50%

EXCLUSIONS:
- Hypersensitivity to pertuzumab, trastuzumab, PACLitaxel, or any of the excipients
- Clinically significant cardiac disease (history of symptomatic ventricular arrhythmias, congestive heart failure or myocardial infarction within previous 12 months)
- Patients experiencing dyspnoea at rest due to complications of advanced malignancy and comorbidities may be at increased risk of a fatal infusion reaction with trastuzumab
- Significant hepatic dysfunction, contraindicating DOCEtaxel
- Baseline neutrophil count < 1.5 x 10\(^9\)/L
- Pregnancy
- Lactation

PRESCRIPTIVE AUTHORITY:
The treatment plan must be initiated by a Consultant Medical Oncologist.
TESTS:

Baseline tests:
- FBC, renal and liver profile
- Cardiac function (LVEF using ECHO or MUGA scan)

Regular tests:
- FBC, renal and liver profile before each cycle
- MUGA scan or echocardiogram every 12 weeks during treatment with trastuzumab and at completion of therapy. Where there are signs of cardiac impairment four to eight weekly checks may be more appropriate.

Disease monitoring:
Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant
- Pertuzumab and trastuzumab
  - None usually recommended. Doses are held or discontinued if unacceptable toxicity occurs.
  - Discontinue pertuzumab if trastuzumab is discontinued.
  - Patient may continue to receive both pertuzumab and trastuzumab if DOCEtaxel is discontinued due to toxicity or after 6-8 cycles and without evidence of disease progression.
- Delayed or missed doses
  - If the time between two sequential infusions is < 6 weeks, the 420 mg dose of pertuzumab should be administered as soon as possible without regard to the next planned dose.
  - Re-load pertuzumab if the time between two sequential infusions is ≥ 6 weeks or more.
  - Re-load trastuzumab if the time between two sequential infusions is ≥ 6 weeks.
  - If re-loading is required for either drug, the 3 drugs should be given in the same schedule as Cycle 1.
  - The next cycle should follow 21 days from the re-loading dose.

Haematological:

<table>
<thead>
<tr>
<th>ANC (x10^9/L)</th>
<th>Platelets</th>
<th>Dose</th>
<th>Dose after neutropenic sepsis</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 1.5</td>
<td>&gt; 90</td>
<td>80mg/m²</td>
<td>65mg/m²</td>
</tr>
<tr>
<td>*1-1.49</td>
<td>or 70-90</td>
<td>65mg/m²</td>
<td>50mg/m²</td>
</tr>
<tr>
<td>&lt; 1</td>
<td>or &lt; 70</td>
<td>Delay and reduce next dose to 65mg/m² or add G-CSF</td>
<td>Delay</td>
</tr>
</tbody>
</table>

Patients who cannot tolerate treatment after 2 dose reductions or require a treatment delay of greater than 2 weeks, should discontinue treatment.

* If ANC 1 to less than 1.5 and patient fit and well can consider full dose of 80 mg/m² at discretion of prescribing Consultant
Renal and Hepatic Impairment:

Table 4: Dose modification in renal and hepatic impairment

<table>
<thead>
<tr>
<th>Drug</th>
<th>Renal Impairment</th>
<th>Hepatic Impairment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pertuzumab</strong></td>
<td>No dose reduction required for mild or moderate renal impairment. No dose recommendations for severe impairment due to limited data.</td>
<td>No specific dose recommendations. Has not been studied in patients with hepatic impairment.</td>
</tr>
<tr>
<td><strong>Trastuzumab</strong></td>
<td>No dose reduction required.</td>
<td>No dedicated studies of trastuzumab in patients with hepatic impairment have been conducted. Probably no dose reduction necessary.</td>
</tr>
<tr>
<td><strong>PACLitaxel</strong></td>
<td>No dose modifications necessary</td>
<td>ALT Total bilirubin Dose of PACLitaxel</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≤ 1.25xULN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.26-2xULN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.01-5xULN</td>
</tr>
<tr>
<td></td>
<td>≥10xULN and/or</td>
<td>&gt;5xULN</td>
</tr>
</tbody>
</table>

Management of adverse events:

Table 5: Dose modification schedule based on adverse events

<table>
<thead>
<tr>
<th>Adverse reactions</th>
<th>Recommended dose modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pertuzumab and Trastuzumab LVEF &lt; 40% or 40-45% associated with ≥10% points below the pretreatment value.</td>
<td>Withhold treatment with pertuzumab and trastuzumab. Repeat LVEF within 3 weeks. No improvement or further decline, consider discontinuation. Discuss with consultant and refer to cardiologist.</td>
</tr>
<tr>
<td>Symptomatic heart failure</td>
<td>Discontinue</td>
</tr>
<tr>
<td>NCI-CTCAE Grade 4 hypersensitivity reactions</td>
<td>Discontinue</td>
</tr>
<tr>
<td>PACLitaxel Grade &gt;2 peripheral neuropathy</td>
<td>Decrease dose by 10mg/m²</td>
</tr>
<tr>
<td>All other grade 2 non-haematological toxicity</td>
<td>Hold treatment until toxicity resolves to ≤ grade 1. Decrease subsequent doses by 10mg/m².</td>
</tr>
<tr>
<td>≥ Grade 3 reaction</td>
<td>Discontinue</td>
</tr>
<tr>
<td>Patients who cannot tolerate treatment after 2 dose reductions or require a treatment delay of greater than 2 weeks, should discontinue treatment</td>
<td></td>
</tr>
</tbody>
</table>

**SUPPORTIVE CARE:**

**EMETOGENIC POTENTIAL:** Low (Refer to local policy).

**PREMEDICATIONS:**
- All patients must be premedicated with corticosteroids, antihistamines, and H₂ antagonists prior to PACLitaxel treatment. Table 6 outlines suggested premedications prior to treatment with PACLitaxel.
NCCP Chemotherapy Regimen

Table 6: Suggested prededications prior to treatment with PACLitaxel

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Administration prior to PACLitaxel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone</td>
<td>10mg IV</td>
<td>30 minutes</td>
</tr>
<tr>
<td>Chlorphenamine</td>
<td>10mg IV</td>
<td>30 minutes</td>
</tr>
<tr>
<td>Ranitidine</td>
<td>50mg IV</td>
<td>30 minutes</td>
</tr>
</tbody>
</table>

* Dose of dexamethasone may be reduced or omitted in the absence of hypersensitivity reaction according to consultant guidance.
* or an equivalent antihistamine e.g. chlorphenamine

- **Trastuzumab and pertuzumab**: Not usually required unless the patient has had a previous hypersensitivity. Paracetamol and antihistamine cover should be considered. Patient should be educated about the possibility of delayed infusion-related symptoms.

**OTHER SUPPORTIVE CARE:**
Myalgias and arthralgias may occur with PACLitaxel. Analgesic cover should be considered.

**ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS**
The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Febrile neutropenia**: Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Hypersensitivity/Infusion reactions**: There is a risk of hypersensitivity/infusion reactions with pertuzumab and PACLitaxel. Although hypersensitivity with trastuzumab is common, severe hypersensitivity reactions are uncommon. Use with caution in patients with dyspnoea at rest from pulmonary/cardiac conditions as increased risk of infusion related symptoms.
- **Cardiac toxicity**: Decreases in LVEF have been reported with medicinal products that block HER2 activity, including pertuzumab. Trastuzumab can produce declines in ventricular dysfunction and congestive heart failure (CHF). Baseline and 3 monthly cardiac function tests are required during treatment especially for those with prior anthracycline exposure.
- **Extravasation**: PACLitaxel causes pain and tissue necrosis if extravasated. (Refer to local policy).
- **Peripheral neuropathy**: Occurs frequently with PACLitaxel but the development of severe symptoms is rare.
- **Arthralgia/myalgia**: May be severe in some patients; however, there is no consistent correlation between cumulative dose and infusion duration of PACLitaxel and frequency or severity of the arthralgia/myalgia. Symptoms are usually transient, occurring within 2 or 3 days after PACLitaxel administration, and resolving within days.
- **Hepatic Dysfunction**: Patients with hepatic impairment may be at increased risk of toxicity with PACLitaxel, particularly grade 3-4 myelosuppression.

**DRUG INTERACTIONS:**
- A possible interaction with warfarin has been reported. An increased INR and bleeding may occur in patients previously stabilized on warfarin. The interaction was noted in two patients after 8-10 doses of trastuzumab. An INR prior to starting the trastuzumab is recommended, then every 2 weeks for the first 3 months and then monthly if stable. Inform patient to watch for any bleeding. Modification of the warfarin dose may be needed.
- Risk of drug interactions causing increased concentrations of PACLitaxel with CYP3A inhibitors. Patients should also be counselled with regard to consumption of grapefruit juice.

---

This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)
• Risk of drug interactions causing decreased concentrations of PACLitaxel with CYP3A inducers.
• Current drug interaction databases should be consulted for more information.

ATC CODE:
Pertuzumab  -  L01XC13
PACLitaxel  -  L01CD01
Trastuzumab  -  L01XC03

REFERENCES:

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

ODMS – Oncology Drug Management System
NCCP Chemotherapy Regimen

NCCP Regimen: Pertuzumab Trastuzumab and Weekly PACLitaxel Therapy – 21 day cycle

Published: 13/08/2018
Review: 19/10/2020
Version number: 2

Tumour Group: Breast
NCCP Regimen Code: 00507

ISMO Contributor: Prof Maccon Keane

Page 7 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient’s care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE’s terms of use available at http://www.hse.ie/eng/Disclaimer

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes

Further details on the Cancer Drug Management Programme is available at; http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/